Cite
Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
MLA
Buse, Dawn C., et al. “Real-World Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.” Pain & Therapy, vol. 13, no. 3, June 2024, pp. 511–32. EBSCOhost, https://doi.org/10.1007/s40122-024-00583-9.
APA
Buse, D. C., Krasenbaum, L. J., Seminerio, M. J., Packnett, E. R., Carr, K., Ortega, M., & Driessen, M. T. (2024). Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. Pain & Therapy, 13(3), 511–532. https://doi.org/10.1007/s40122-024-00583-9
Chicago
Buse, Dawn C., Lynda J. Krasenbaum, Michael J. Seminerio, Elizabeth R. Packnett, Karen Carr, Mario Ortega, and Maurice T. Driessen. 2024. “Real-World Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.” Pain & Therapy 13 (3): 511–32. doi:10.1007/s40122-024-00583-9.